Zelluna ASA | ULTI - Profile, Filings, Stock Info & Investor Relations Data

Zelluna’s mission is to eliminate solid cancers by unleashing the most powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies. The team comprises experienced biotech entrepreneurs that have taken immune-oncology projects from inception through to the clinic and supported by a highly experienced international board

We are committed to provide benefit to patients, their families and all those around them, by developing therapies that bring together TCR guidance with the effector functions of allogeneic NK cells (TCR-NK) deploying a mechanism of action that we believe has the potential to be both safe and potent. This platform has unique advantages providing “off-the-shelf” access to an advanced therapy for large patient populations.